In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients. .
【中文题目：BRAF融合在非小细胞肺癌中的研究进展】 【中文摘要：在晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）中，鼠类肉瘤病毒癌基因同源物B1（V-Raf murine sarcoma viral oncogene homolog B1, BRAF）突变恶性程度高、预后差，目前达拉非尼联合曲美替尼被批准用于BRAF V600突变患者的一线治疗。BRAF除了突变外，还可以发生融合，随着基因检测的发展，BRAF融合的检出逐渐增多，但是对于BRAF融合的治疗缺乏有效的治疗策略。本文从BRAF融合的临床特点、作用机制、临床治疗等方面进行综述，加强对BRAF基因融合的认识，为BRAF融合在NSCLC患者的治疗方面提供理论依据。 】 【中文关键词：肺肿瘤；鼠类肉瘤病毒癌基因同源物B1；融合】.
Keywords: Fusion; Lung neoplasms; V-Raf murine sarcoma viral oncogene homolog B1.